NCI and ECOG-ACRIN officials said the NCI-MATCH trial will keep going, continuing to match patients with treatment arms based primarily on their molecular characteristics.
The first step in the NCI-MATCH trial—deciding how many patients to screen—was a guess.
The new iteration of the NCI-MATCH trial will test the ability on the part of cancer researchers to integrate exchanges of genomic information between academic institutions and commercial vendors, said James Doroshow, NCI deputy director for clinical and translational research and director of the Division of Cancer Treatment and Diagnosis
Steven Leach was named director of the Norris Cotton Cancer Center. He will begin his role in September.
Chi Van Dang was appointed professor at The Wistar Institute.
Patricia Ganz will replace Carmen Allegra as editor-in-chief of JNCI.
The Society for Translational Oncology Fellows' Forum is accepting applications through July 31.
FDA cleared the expanded use of a cooling cap, DigniCap Cooling System, to reduce hair loss during chemotherapy.
FDA granted marketing approval June 29 to the Praxis Extended RAS Panel, a next generation sequencing test to detect certain genetic mutations in RAS genes in tumor samples of patients with metastatic colorectal cancer. The test is used to aid in the identification of patients who may be eligible for treatment with panitumumab (Vectibix, Amgen, Inc.).
FDA approved Endari (L-glutamine oral powder) for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder.
